FARGO, N.D. (September 11, 2023) – Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition. She replaces Kevin Ballinger, who has departed Aldevron after leading the organization for three years.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA, and proteins for the biotech industry, signed a licensing agreement with Genentech, a member of the Roche Group, to use Aldevron’s proprietary Nanoplasmid® vector technology.
Aldevron, Jennifer Doudna, and Innovative Genomics Institute Collaborate on In Vivo CRISPR Therapies for Neurologic Diseases. Resulting paper published in Molecular Therapy.
FARGO, N.D. (August 29, 2023)— Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS. Aldevron supplied custom CRISPR protein with ultra-low endotoxin, enabling direct delivery to the brain in mice. This partnership resulted in a paper, titled “Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs,” published in the journal Molecular Therapy, the official journal of the American Society of Gene and Cell Therapy.
The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process requiring a high degree of expertise, capabilities, and experience. The development and manufacturing of drug product involves several stages that include production of cell banks, linear DNA, and mRNA drug substance, with lipid nanoparticle (LNP) formulation/encapsulation and analytical testing at all steps, through aseptic fill/finish.
Demand for mRNA continues to rise and earlier this Spring, we announced the expansion of our mRNA custom manufacturing— going from a cell bank to a drug product — to help meet demand. Doing that required combining our capabilities with the technologies and expertise of two other Danaher companies, Cytiva and Precision NanoSystems Inc. (PNI). Genetic Engineering News covered the story, interviewing Todd Howren/ PhD, Aldevron's VP of RNA.
Will offer mRNA cGMP Production from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva
Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product. This new capability will support the production of therapeutic-scale clinical and commercial-stage mRNA therapies for cancers and genetic diseases, and clinical-stage vaccines for infectious diseases.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.
On the pathway to GMP manufacturing in support of clinical trials, multiple technology transfers may correlate to an increase in complexity and risk to both product and timeline. The hand-off of new technologies, protocols, and materials can lead to delays or project failures.